DRDavid Rekhtman

David Rekhtman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Rekhtman has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of extended criteria donor cardiac allografts after multiple offers is associated with inferior post-transplant outcomes

    by Cindy Song, Amit Iyengar, David Rekhtman, Michaela Asher, Max Shin, Noah Weingarten, Omar Toubat, Mauer Biscotti, Marisa Cevasco


    • 1 March 2026
      • Vol. 40  (3) , e70452
    Open Access

    Impact of Prolonged Impella 5.5 Support on Post-Transplant Outcomes: An Institutional Study.

    by David Rekhtman, Amit Iyengar, Cindy Song, Michaela Asher, Max Shin, Michael Catalano, Omar Toubat, Emma Morganroth, Alyson Brown, Joyce Wald, et al.

    Microaxial flow pump devices are utilized as a bridge to heart transplantation for patients in advanced cardiogenic shock. Little is known about the impact of device duration on post-transplant outcomes. This study aims to compare post-transplantation outcomes based on duration of support with the Impella 5.5. All patients who were successfully bridged to transplant on the Impella 5.5 platform were included and stratified based on support duration (≤ 14 days vs. > 14 days). Baseline clinical characteristics were collected throughout the index admission. Outcomes included 1-year mortality, complications during the index admission, graft rejection, and rehospitalization within the first year. Of the 72 patients successfully bridged to transplant, 64% (n = 46) were supported for more than 14 days. When stratified by duration of Impella 5.5 use, there were no differences in pretransplantation clinical status. Length of stay (26 vs. 20 days, p = 0.316) and rates of home discharges (65% vs. 67%, p = 0.524) were similar. Despite a high prevalence of rehospitalization at 1 year (75%), the 1-year survival was 96% and similar between the two cohorts (p = 0.289). Use of a prolonged microaxial flow pump may be a safe bridging strategy for heart transplantation given comparable post-transplant outcomes for patients stratified by support duration.

  • Open Access

    Impact of Prolonged Impella 5.5 Support on Post‐Transplant Outcomes: An Institutional Study

    by David Rekhtman, Amit Iyengar, Cindy Song, Michaela Asher, Max Shin, Michael Catalano, Omar Toubat, Emma Morganroth, Alyson Brown, Joyce Wald, et al.

    Objectives: Microaxial flow pump devices are utilized as a bridge to heart transplantation for patients in advanced cardiogenic shock. Little is known about the impact of device duration on post‐transplant outcomes. This study aims to compare post‐transplantation outcomes based on duration of support with the Impella 5.5. Methods: All patients who were successfully bridged to transplant on the Impella 5.5 platform were included and stratified based on support duration (≤ 14 days vs. > 14 days). Baseline clinical characteristics were collected throughout the index admission. Outcomes included 1‐year mortality, complications during the index admission, graft rejection, and rehospitalization within the first year. Results: Of the 72 patients successfully bridged to transplant, 64% (n = 46) were supported for more than 14 days. When stratified by duration of Impella 5.5 use, there were no differences in pretransplantation clinical status. Length of stay (26 vs. 20 days, p = 0.316) and rates of home discharges (65% vs. 67%, p = 0.524) were similar. Despite a high prevalence of rehospitalization at 1 year (75%), the 1‐year survival was 96% and similar between the two cohorts ( p = 0.289). Conclusions: Use of a prolonged microaxial flow pump may be a safe bridging strategy for heart transplantation given comparable post‐transplant outcomes for patients stratified by support duration.


  • Open Access

    Postoperative Hyponatremia After Pleural Symphysis

    by Cheryssa Hislop, David Rekhtman, Karina Bruestle, Sunil Singhal

  • Open Access

    Beyond Online Course Evaluations: Student-Led Focus Groups for Curricular Feedback

    by David Rekhtman, Jessica Campanile, Alex F. Nisbet, Abigail Kohler, Jennifer Hong, Ish Sethi, Suzanne Rose, C. Jessica Dine

    Purpose: Medical student curricular evaluation is both beneficial and required. Most medical schools rely on online questionnaires for evaluations, but these are often overlooked or completed haphazardly. We describe the implementation of focus groups as a supplemental form of curricular assessment and evaluate students’ and faculty members’ attitudes towards this novel approach.Method: Ten randomly selected students were assigned to eight focus groups regarding three different preclerkship courses. Following the completion of focus groups, interviews were conducted with students who participated in them, course directors who received the focus group reports, and administrators who oversaw the preclerkship curriculum and the implementation of the focus group program. The semi-structured interviews were then analyzed using inductive thematic analysis, with initial codes generated from the data and subsequent interpretation informed by prior literature on feedback relationships and curricular program evaluation.Results: Interviews were conducted with 17 students, 5 faculty members, and 3 administrators. Participants highlighted key themes related to trust, engagement, collaboration, and the learning environment. Students described the focus groups as a safe space and said they enjoyed thinking critically about improvements. Faculty perceived the thematic content of focus group reports to be comparable to course evaluation summaries from established online forms despite concerns for a smaller sample size.Conclusions: Focus groups are a novel supplemental tool that can complement existing evaluation mechanisms. Engaging students through focus groups can improve feedback and advance medical school curricula, resulting in a more responsive and adaptive approach to education.

  • Open Access

    Impella 5.5 use in women: A multicenter study

    by Michaela Asher, David Rekhtman, Amit Iyengar, John DePaolo, Cindy Song, Iris Feng, Emma Morganroth, Gabriel Dardik, Max Shin, Noah Weingarten, et al.


  • Prolonged Impella 5.5 Support in a Pediatric Patient With Genetic Cardiomyopathy

    by David Rekhtman, Michaela Asher, Cindy Song, Amit Iyengar, Marisa Cevasco, Katsuhide Maeda, Constantine D. Mavroudis

    Temporary mechanical circulatory support (tMCS) has been utilized as a bridge to heart transplantation with increasing duration of support. We describe the clinical course of a 14-year-old patient, with TNNT2 and KCNQ1 mutations, requiring Impella 5.5 support for 76 days. We discuss the patient's underlying genetic etiology, potential complications of prolonged tMCS, and the importance of multidisciplinary support. To our knowledge, this is the first published case in which a patient has this specific combination of genetic mutations and the longest published support duration of an Impella 5.5 in a pediatric patient.


  • Superior Waitlist Outcomes Among Patients Listed for Donation After Circulatory Death Heart Transplantation

    by Max Shin, Omar Toubat, Michael A. Catalano, Amit Iyengar, Mark R. Helmers, Michaela Asher, David Rekhtman, Cindy Song, Mauer Biscotti, Marisa Cevasco


  • Acute Hemodynamic and Echocardiographic Consequences of Impella 5.5 Placement in Patients With Advanced Cardiogenic Shock

    by Michaela Asher, Amit Iyengar, David Rekhtman, Mark Helmers, Noah Weingarten, Cindy Song, John DePaolo, Max Shin, Alyson Brown, Joyce Wald, et al.

    We sought to investigate the hemodynamic and echocardiographic consequences of the Impella 5.5 during the acute perioperative period. A retrospective analysis of patients who underwent device implantation at our institution between January 2021 and June 2023 was performed. Hemodynamic and echocardiographic changes were modeled as linear mixed models with random intercepts for patient and fixed as well as random effects of time. Of 87 patients identified, most were male (72, 83%) with nonischemic cardiomyopathy (44, 51%). In the first two postoperative days, the median cardiac output increased by 1.2 L/min (p < 0.05), although the median Impella flow remained at 4.1 L/min. Mean pulmonary artery pressures (32 vs. 27 mm Hg, p < 0.05) and vasoactive inotrope scores (5.6 vs. 3.7, p < 0.01) were modestly reduced. Significant echocardiographic improvement was noted in 61% and 71% of patients with significant preoperative mitral or tricuspid regurgitation, respectively. However, no changes in ejection fraction, left ventricle (LV) diameter, or right ventricular function were noted (all p > 0.05). At 30 days, 27 (31%) patients were transplanted and 13 (15%) were bridged to a durable left ventricular assist device (LVAD). We conclude that in the acute phase following Impella implantation, LV offloading, reductions in pulmonary artery pressures, and improvement in valvular regurgitation are seen without changes to ventricular geometry.


  • Open Access

    Epidemiology and impact of device-specific infections on patients receiving left ventricular assist devices

    by Amit Iyengar, Jason Feinman, Joyce Jiang, Cindy Song, Spencer Kim, Alvin Mathew, Sophia Golec, Aarti Rao, Ankitha Radakrishnan, Michaela Asher, et al.